Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | DAO | P14920 | 2/20 | 0.37 |
| ▸ | TSHR | P16473 | 1/20 | 0.37 |
| ▸ | CA12 | O43570 | 2/20 | 0.37 |
| ▸ | CA1 | P00915 | 2/20 | 0.37 |
| ▸ | CA2 | P00918 | 2/20 | 0.37 |
| ▸ | CA3 | P07451 | 2/20 | 0.37 |
| ▸ | CA4 | P22748 | 2/20 | 0.37 |
| ▸ | CA6 | P23280 | 2/20 | 0.37 |
| ▸ | CA5A | P35218 | 2/20 | 0.37 |
| ▸ | CA7 | P43166 | 2/20 | 0.37 |
| ▸ | CA9 | Q16790 | 2/20 | 0.37 |
| ▸ | CA13 | Q8N1Q1 | 2/20 | 0.37 |
| ▸ | CA14 | Q9ULX7 | 2/20 | 0.37 |
| ▸ | CA5B | Q9Y2D0 | 2/20 | 0.37 |
| ▸ | LMNA | P02545 | 2/20 | 0.36 |
| ▸ | ALDH1A1 | P00352 | 2/20 | 0.36 |
| ▸ | MAPK1 | P28482 | 1/20 | 0.36 |
| ▸ | HSD17B10 | Q99714 | 1/20 | 0.33 |
| ▸ | CISD1 | Q9NZ45 | 1/20 | 0.33 |
| ▸ | AKR1C4 | P17516 | 1/20 | 0.32 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL4648490 | 0.81 | CA2 (0.49) | TSHRCA12CA1CA2CA3 | |
| SCHEMBL21962166 | 0.80 | NPSR1 (0.42) | TSHRCA12CA1CA2CA5A | |
| SCHEMBL6819822 | 0.79 | DAO (0.57) | DAOTSHRCA12CA1CA2 | |
| SCHEMBL16236942 | 0.78 | ALDH1A1 (0.43) | DAOTSHRCA12CA1CA2 | |
| SCHEMBL630120 | 0.74 | LMNA (0.41) | LMNAKMT2A | |
| SCHEMBL15056083 | 0.72 | MAPT (0.34) | TSHRCA1CA2CA9LMNA | |
| SCHEMBL623602 | 0.71 | TSHR (0.45) | DAOTSHRCA12CA1CA2 | |
| SCHEMBL4534390 | 0.71 | GAA (0.31) | LMNA | |
| Hydrochloric Acid SCHEMBL29045760 | 0.70 | TSHR (0.43) | DAOTSHRCA12CA1CA2 | |
| SCHEMBL2825614 | 0.68 | ALDH1A1 (0.53) | DAOTSHRLMNAALDH1A1MAPK1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 6 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-10160743-B2 | Sulphamoylthiophenamide derivatives and the use thereof as medicaments for the treatment of hepatitis B | JANSSEN SCIENCES IRELAND UC (IE) | 2018-12-25 | — | — | US | disclosed |
| EP-2997019-B1 | SULPHAMOYLTHIOPHENAMIDE DERIVATIVES AND THE USE THEREOF AS MEDICAMENTS FOR THE TREATMENT OF HEPATITIS B | JANSSEN SCIENCES IRELAND UC (IE) | 2018-08-08 | — | — | EP | disclosed |
| CN-105960400-A | Sulphamoylthiophenamide derivatives and the use thereof as medicaments for the treatment of hepatitis b | 爱尔兰詹森科学公司 | 2016-09-21 | — | — | CN | disclosed |
| US-20160115149-A1 | SULPHAMOYLTHIOPHENAMIDE DERIVATIVES AND THE USE THEREOF AS MEDICAMENTS FOR THE TREATMENT OF HEPATITIS B | JANSSEN SCIENCES IRELAND UC (IE) | 2016-04-28 | — | — | US | disclosed |
| EP-2997019-A1 | SULPHAMOYLTHIOPHENAMIDE DERIVATIVES AND THE USE THEREOF AS MEDICAMENTS FOR THE TREATMENT OF HEPATITIS B | Janssen Sciences Ireland UC (IE) | 2016-03-23 | — | — | EP | disclosed |
| WO-2014184365-A1 | SULPHAMOYLTHIOPHENAMIDE DERIVATIVES AND THE USE THEREOF AS MEDICAMENTS FOR THE TREATMENT OF HEPATITIS B | JANSSEN R&D IRELAND (IE) | 2014-11-20 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-10160743-B2 | Sulphamoylthiophenamide derivatives and the use thereof as medicaments for the treatment of hepatitis B | HBS1L, SLC10A1, NR1H4 | DAO 3447/4885TSHR 2253/4885CA12 3183/4885 |
| US-20160115149-A1 | SULPHAMOYLTHIOPHENAMIDE DERIVATIVES AND THE USE THEREOF AS MEDICAMENTS FOR THE TREATMENT OF HEPATITIS B | HBS1L, SLC10A1, NR1H4 | DAO 3447/4885TSHR 2253/4885CA12 3183/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.